[{"address1": "685 Route 202/206 N", "address2": "Suite 301", "city": "Bridgewater", "state": "NJ", "zip": "08807", "country": "United States", "phone": "800 775 7936", "website": "https://www.vynetherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.", "fullTimeEmployees": 10, "maxAge": 86400, "priceHint": 4, "previousClose": 1.76, "open": 1.75, "dayLow": 1.75, "dayHigh": 1.86, "regularMarketPreviousClose": 1.76, "regularMarketOpen": 1.75, "regularMarketDayLow": 1.75, "regularMarketDayHigh": 1.86, "beta": 1.485, "forwardPE": -2.3037975, "volume": 116267, "regularMarketVolume": 116267, "averageVolume": 92716, "averageVolume10days": 98060, "averageDailyVolume10Day": 98060, "marketCap": 26441324, "fiftyTwoWeekLow": 1.67, "fiftyTwoWeekHigh": 6.789, "priceToSalesTrailing12Months": 62.50904, "fiftyDayAverage": 2.5012, "twoHundredDayAverage": 2.728245, "currency": "USD", "enterpriseValue": -59328592, "floatShares": 9874849, "sharesOutstanding": 14528200, "sharesShort": 57356, "sharesShortPriorMonth": 96825, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0039, "heldPercentInsiders": 0.0846, "heldPercentInstitutions": 0.57021, "shortRatio": 1.0, "shortPercentOfFloat": 0.004, "impliedSharesOutstanding": 14528200, "bookValue": 5.829, "priceToBook": 0.31223196, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -28650000, "trailingEps": -1.13, "forwardEps": -0.79, "pegRatio": -0.01, "lastSplitFactor": "1:18", "lastSplitDate": 1676246400, "enterpriseToRevenue": -140.257, "52WeekChange": -0.61194026, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "VYNE", "underlyingSymbol": "VYNE", "shortName": "VYNE Therapeutics Inc.", "longName": "VYNE Therapeutics Inc.", "firstTradeDateEpochUtc": 1516890600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "6b428866-1c06-3cdf-aea1-c192e2cb997e", "messageBoardId": "finmb_6511914", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.82, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 85950000, "totalCashPerShare": 5.916, "totalDebt": 180000, "quickRatio": 12.403, "currentRatio": 13.019, "totalRevenue": 423000, "debtToEquity": 0.216, "revenuePerShare": 0.021, "returnOnAssets": -0.30293, "returnOnEquity": -0.51914, "freeCashflow": -17962876, "operatingCashflow": -27845000, "revenueGrowth": -0.01, "grossMargins": 1.0, "operatingMargins": -75.30612, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]